We've already released two bespoke eBooks focusing on Nordic startups and private companies respectively. The Nordic region has long produced world-leading science and innovation. Despite this, growth and venture funding is lacking compared with other hubs and Nordic companies face a number of specific challenges in their ongoing funding, growth, development and internationalisation. We're now pleased to announce the final part of this series, showcasing the public life sciences companies in the Nordics that you need to know.
As a taster of what's in the eBook, take a look below at 5 of our Nordic public companies that should be on your radar in 2019.
Acarix A/S is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004. The research group received the award, ‘MedicoPrisen’, from Medicoindustrien (Danish Medtech trade association) in 2007. A research and development collaboration was established in 2007 between Aalborg University and Coloplast A/S, receiving public support from the Danish National Advanced Technology Foundation in 2008.
Asarina Pharma is developing novel and targeted products to treat women with severe symptoms associated with the menstrual cycle such as premenstrual dysphoric disorder (PMDD), allowing these women to remain in control of their own life.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Mentice is the world leader in virtual reality‐based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and preprocedural planning—leading to improved productivity and outcomes.
ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark. Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 300 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare.
Take a look at all of the Nordic public companies coming to the 2nd LSX Nordic Congress, Stockholm, 28-29 August.